These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 10228084

  • 1. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.
    Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.
    J Infect Dis; 1999 Jun; 179(6):1565-8. PubMed ID: 10228084
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group.
    Pediatr Infect Dis J; 2003 Aug; 22(8):701-6. PubMed ID: 12913770
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
    Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R.
    Infect Immun; 2001 Mar; 69(3):1351-7. PubMed ID: 11179298
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, Kubler-Kielb J, Vinogradov E, Robbins JB, Schneerson R.
    Vaccine; 2017 Sep 05; 35(37):4990-4996. PubMed ID: 28797729
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
    Oaks EV, Turbyfill KR.
    Vaccine; 2006 Mar 20; 24(13):2290-301. PubMed ID: 16364513
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, Bialik A, Asato V, Meron-Sudai S, Frankel G, Cohen D, Chilengi R.
    PLoS One; 2021 Mar 20; 16(5):e0252222. PubMed ID: 34043697
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a.
    Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN.
    Vaccine; 2007 Jun 15; 25(25):4828-36. PubMed ID: 17507120
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children.
    Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC.
    J Infect Dis; 2006 Feb 15; 193(4):515-21. PubMed ID: 16425130
    [Abstract] [Full Text] [Related]

  • 14. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains.
    Mel D, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S.
    Bull World Health Organ; 1971 Feb 15; 45(4):457-64. PubMed ID: 4948417
    [Abstract] [Full Text] [Related]

  • 15. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.
    Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB.
    Lancet; 1997 Jan 18; 349(9046):155-9. PubMed ID: 9111538
    [Abstract] [Full Text] [Related]

  • 16. Construction of a stable and non-resistant bivalent vaccine candidate strain against Shigella flexneri 2a and Shigella sonnei.
    Rui X, Xu Y, Wan H, Su G, Huang C.
    Chin J Biotechnol; 1996 Jan 18; 12(2):89-97. PubMed ID: 8988355
    [Abstract] [Full Text] [Related]

  • 17. Shigella lipopolysaccharide antibodies in pediatric populations.
    Passwell JH, Freier S, Shor R, Farzam N, Block C, Lison M, Shiff E, Ashkenazi S.
    Pediatr Infect Dis J; 1995 Oct 18; 14(10):859-65. PubMed ID: 8584312
    [Abstract] [Full Text] [Related]

  • 18. Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study.
    Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, Weerts HE, Duplessis C, Castellano A, Alaimo C, Paolino K, Gormley R, Gambillara Fonck V.
    Clin Vaccine Immunol; 2016 Dec 18; 23(12):908-917. PubMed ID: 27581434
    [Abstract] [Full Text] [Related]

  • 19. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG.
    EBioMedicine; 2021 Apr 18; 66():103310. PubMed ID: 33862589
    [Abstract] [Full Text] [Related]

  • 20. [Expression of S.sonnei form I antigen gene and V.cholerae toxin B subunit gene in S.flexneri 2a strain and investigation of their immunoprotective response in mice].
    Qian F, Rui X, Su G, Huang C.
    Yi Chuan Xue Bao; 1996 Apr 18; 23(4):322-8. PubMed ID: 8950856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.